Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glucagon-like peptide-1 (9-36) is the primary metabolite of the incretin hormone GLP-1 (7-36) amide, formed by the enzymatic action of dipeptidyl peptidase-4 (DPP-4). While it was historically considered an inactive metabolite due to its lack of insulinotropic effect, recent studies have highlighted its potential cardiovascular benefits. Specifically, it is being investigated for its ability to improve coronary microcirculation and endothelial function in patients with obesity and coronary microvascular dysfunction. These effects appear to be mediated through a mechanism that is independent of the canonical Glucagon-like peptide 1 receptor (GLP-1R), suggesting the existence of alternative signaling pathways in the vascular endothelium.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glucagon-like peptide-1 (9-36).